Get started
Lexaria Bioscience Corp.Lexaria Bioscience Corp.Lexaria Bioscience Corp.

Lexaria Bioscience Corp.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

LEXX chart


Full chart

LEXX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪18.70 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.5839 USD
Net income (FY)
‪−5.80 M‬ USD
Revenue (FY)
‪464.28 K‬ USD
Shares float
‪18.06 M‬
Beta (1Y)
0.57

Employees


Employees (FY)
7
Change (1Y)
+2 +40.00%
Revenue / Employee (1Y)
‪66.33 K‬ USD
Net income / Employee (1Y)
‪−827.91 K‬ USD

About Lexaria Bioscience Corp.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Richard C. Christopher
Website
lexariabioscience.com
Headquarters
Kelowna
Founded
2004
FIGI
BBG000JQHT18
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

LEXX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as LEXX.

Frequently Asked Questions


The current price of LEXX is 0.9752 USD — it has increased by 2.36% in the past 24 hours. Watch Lexaria Bioscience Corp. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Lexaria Bioscience Corp. stocks are traded under the ticker LEXX.
LEXX stock has fallen by −6.41% compared to the previous week, the month change is a −30.30% fall, over the last year Lexaria Bioscience Corp. has showed a −66.60% decrease.
We've gathered analysts' opinions on Lexaria Bioscience Corp. future price: according to them, LEXX price has a max estimate of 8.00 USD and a min estimate of 6.00 USD. Watch LEXX chart and read a more detailed Lexaria Bioscience Corp. stock forecast: see what analysts think of Lexaria Bioscience Corp. and suggest that you do with its stocks.
LEXX reached its all-time high on Oct 12, 2007 with the price of 180.0000 USD, and its all-time low was 0.2182 USD and was reached on Nov 21, 2012. View more price dynamics on LEXX chart.
See other stocks reaching their highest and lowest prices.
LEXX stock is 6.32% volatile and has beta coefficient of 0.57. Track Lexaria Bioscience Corp. stock price on the chart and check out the list of the most volatile stocks — is Lexaria Bioscience Corp. there?
Today Lexaria Bioscience Corp. has the market capitalization of ‪18.70 M‬, it has increased by 2.88% over the last week.
Yes, you can track Lexaria Bioscience Corp. financials in yearly and quarterly reports right on TradingView.
Lexaria Bioscience Corp. is going to release the next earnings report on Jul 18, 2025. Keep track of upcoming events with our Earnings Calendar.
LEXX earnings for the last quarter are −0.17 USD per share, whereas the estimation was −0.16 USD resulting in a −1.02% surprise. The estimated earnings for the next quarter are −0.16 USD per share. See more details about Lexaria Bioscience Corp. earnings.
Lexaria Bioscience Corp. revenue for the last quarter amounts to ‪174.00 K‬ USD, despite the estimated figure of ‪150.00 K‬ USD. In the next quarter, revenue is expected to reach ‪174.00 K‬ USD.
LEXX net income for the last quarter is ‪−2.71 M‬ USD, while the quarter before that showed ‪−2.70 M‬ USD of net income which accounts for −0.35% change. Track more Lexaria Bioscience Corp. financial stats to get the full picture.
No, LEXX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 22, 2025, the company has 7 employees. See our rating of the largest employees — is Lexaria Bioscience Corp. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Lexaria Bioscience Corp. EBITDA is ‪−9.20 M‬ USD, and current EBITDA margin is ‪−1.21 K‬%. See more stats in Lexaria Bioscience Corp. financial statements.
Like other stocks, LEXX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Lexaria Bioscience Corp. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Lexaria Bioscience Corp. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Lexaria Bioscience Corp. stock shows the strong sell signal. See more of Lexaria Bioscience Corp. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.